Iressa launched for lung cancer

Iressa (gefitinib) is a new treatment for locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK.

Gefitinib is an antagonist of the epidermal growth factor receptor tyrosine kinase (EGFR-TK). In cancer cells, EGFR-TK-activating mutations contribute to cell survival, proliferation and metastasis.

Physicians should assess EGFR mutation status before administering gefinitib, as there is no evidence that the drug is effective in patients whose tumours lack EGFR mutations.

Interstitial lung disease is common in gefitinib-treated patients and can be severe; if this complication develops, the drug should be discontinued.

View Iressa drug record

Further information: AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)